<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; placebo</title>
	<atom:link href="http://www.tapanray.in/tag/placebo/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Big Pharma Demands Transparency, Keeping their &#8216;Black-Boxes&#8217; Tight and Safe?</title>
		<link>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe</link>
		<comments>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/#comments</comments>
		<pubDate>Mon, 28 Oct 2013 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Black]]></category>
		<category><![CDATA[box]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[ghostwriting]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revelation]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[samples]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[sponsorship]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tight]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wasteful]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2780</guid>
		<description><![CDATA[Pharmaceutical Industry across the globe wants absolute transparency in all government laws, policies, guidelines, transactions and overall governance. They also expect the trade environment should be predictable, non-manipulative and business-friendly. These expectations are indeed well justified and deserve whole-hearted support &#8230; <a href="http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug, Patent and Hype: Quo Vadis Pharma Innovation?</title>
		<link>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-patent-and-hype-quo-vadis-pharma-innovation</link>
		<comments>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/#comments</comments>
		<pubDate>Sun, 20 Oct 2013 18:30:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Columbia]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[discover]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[Hype]]></category>
		<category><![CDATA[indications]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Judgment]]></category>
		<category><![CDATA[Nature]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patentable]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Prescire]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Progress]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Reviews]]></category>
		<category><![CDATA[sans]]></category>
		<category><![CDATA[Section(3d)]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2704</guid>
		<description><![CDATA[A recent research report reveals, though the pharmaceutical companies in the United States since mid 2000 have spent over US$ 50 billion every year to discover new drugs, they have very rarely been able to invent something, which can be called significant &#8230; <a href="http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-patent-and-hype-quo-vadis-pharma-innovation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New ‘Patient Compensation’ Norms on Clinical Trials in India: Overdue Action, Sharp Reaction and Ethical Issues</title>
		<link>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues</link>
		<comments>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/#comments</comments>
		<pubDate>Mon, 25 Feb 2013 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[action]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[controlled]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[CRO]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[experts]]></category>
		<category><![CDATA[GSR]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ISCR]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[negligence]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[norms]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[overdue]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reaction]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1996</guid>
		<description><![CDATA[Responding to the damning stricture made by the Supreme Court on January 3, 2013, the Ministry of Health, as expected, by a gazette notification of January 30, 2013 has made the norms of compensation to patients participating in Clinical Trials &#8230; <a href="http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-patient-compensation-norms-on-clinical-trials-in-india-overdue-action-sharp-reaction-and-ethical-issues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
